What percentage of ophthalmologists have adopted AI screening tools?

Few questions divide a room of eye-care professionals faster than "do you use AI in your clinic?" For some, autonomous diabetic-retinopathy screening is already routine; for others, it's a promising tool they're still watching from the sidelines. So where does adoption actually stand — and what's holding the rest back?

A note on the numbers: adoption is moving quickly and estimates vary by country, setting and survey. The figures below are directional ranges drawn from published surveys and clinician sentiment, not a single definitive statistic — treat them as a snapshot of a fast-changing picture.

Where adoption is furthest along

The clearest foothold is diabetic retinopathy screening, where autonomous and assistive systems have regulatory clearance in several markets and slot neatly into high-volume primary-care and endocrinology pathways. Close behind are OCT and fundus-image triage tools that flag likely pathology and help prioritise which patients are seen first. In these narrow, well-validated tasks, AI has moved from novelty to workflow.

Where clinicians stay cautious

Enthusiasm cools for anything approaching a diagnosis or treatment decision. The recurring concerns are consistent:

• Validation and generalisability — does the model hold up on my patient population and my devices?
• Liability — who is responsible when the algorithm is wrong?
• Workflow and reimbursement — does it save time and get paid for, or add clicks?
• Explainability — can I understand and defend the recommendation?

The question is shifting from "does it work?" to "does it fit my clinic, my patients and my liability?"

What tends to move a skeptic

Adoption rarely turns on a single trial. It usually takes three things together: local validation a clinician trusts, a workflow that genuinely saves time, and peers who have used the tool and can speak plainly about the trade-offs. That last factor is easy to underestimate — physicians consistently rate colleagues as their most trusted source when weighing a new technology.

Where this is heading

The trajectory is clear even if the exact percentages aren't: screening and triage adoption will keep climbing as evidence and reimbursement mature, while decision-support tools advance more slowly and under closer scrutiny. The clinicians who benefit most won't be the earliest or the last adopters — they'll be the ones staying close to the evidence and to each other, adopting deliberately rather than reactively.